642 related articles for article (PubMed ID: 25695342)
1. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
[TBL] [Abstract][Full Text] [Related]
2. Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Hupp MM; Bashleben C; Cardinali JL; Dorfman DM; Karlon W; Keeney M; Leith C; Long T; Murphy CE; Pillai V; Rosado FN; Seegmiller AC; Linden MA
Arch Pathol Lab Med; 2021 Mar; 145(3):336-342. PubMed ID: 32886757
[TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
4. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
5. Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.
Björklund E; Matinlauri I; Tierens A; Axelsson S; Forestier E; Jacobsson S; Ahlberg AJ; Kauric G; Mäntymaa P; Osnes L; Penttilä TL; Marquart H; Savolainen ER; Siitonen S; Torikka K; Mazur J; Porwit A
J Pediatr Hematol Oncol; 2009 Jun; 31(6):406-15. PubMed ID: 19648789
[TBL] [Abstract][Full Text] [Related]
6. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
7. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
8. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
9. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.
Böttcher S
Methods Mol Biol; 2019; 1956():157-197. PubMed ID: 30779035
[TBL] [Abstract][Full Text] [Related]
10. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
Luria D; Rosenthal E; Steinberg D; Kodman Y; Safanaiev M; Amariglio N; Avigad S; Stark B; Izraeli S;
Cytometry B Clin Cytom; 2010 Nov; 78(6):365-71. PubMed ID: 20632326
[TBL] [Abstract][Full Text] [Related]
13. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
Cherian S; Soma LA
Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
15. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
16. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
[TBL] [Abstract][Full Text] [Related]
17. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
Zwick D; Cooley L; Hetherington M
Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease studies by flow cytometry in acute leukemia.
Campana D; Coustan-Smith E
Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
